US 12,465,641 B2
Chimeric antigen receptor therapies for treating solid tumors
Dina Schneider, Potomac, MD (US); Peirong Hu, Ijamsville, MD (US); Tri Minh Tran, Frederick, MD (US); Brittany Steimle, Gaithersburg, MD (US); and Aldo Sotelo, Sandy, UT (US)
Assigned to LENTIGEN TECHNOLOGY, INC., Gaithersburg, MD (US)
Filed by LENTIGEN TECHNOLOGY, INC., Gaithersburg, MD (US)
Filed on Aug. 1, 2023, as Appl. No. 18/228,770.
Application 18/228,770 is a continuation of application No. PCT/US2023/029008, filed on Jul. 28, 2023.
Claims priority of provisional application 63/433,632, filed on Dec. 19, 2022.
Claims priority of provisional application 63/393,088, filed on Jul. 28, 2022.
Prior Publication US 2024/0091360 A1, Mar. 21, 2024
Int. Cl. A61P 35/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 15/86 (2006.01)
CPC A61K 40/421 (2025.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4202 (2025.01); A61K 40/4255 (2025.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/2827 (2013.01); C07K 16/30 (2013.01); C12N 15/86 (2013.01); C07K 2319/03 (2013.01); C12N 2740/15043 (2013.01)] 10 Claims
 
1. A method of treating a ROR1+-cancer in a subject in need thereof, the method comprising administering to the subject having the ROR1+-cancer a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the T cells comprise a constitutive promoter operably linked to a nucleic acid sequence that encodes a single chimeric antigen receptor (CAR) with one or more booster elements, a tandem CAR with one or more booster elements, a multi-targeting CAR with one or more booster elements, or a DuoCAR with one or more booster elements, wherein the CAR of the single CAR with one or more booster elements, the tandem CAR with one or more booster elements, the multi-targeting CAR with one or more booster elements, or the DuoCAR with one or more booster elements comprises the amino acid sequence of SEQ ID NO: 152, 154, 156, 160, 162, 164, 174, 176, 178, 180, 182, 184, 192, 194, 196, 198, 227, 233, 235, 237, 239, 241, 243, 252, 254, or 256, wherein the T cells are T cells of the subject having the ROR+-cancer.